Read & Download your Issue of Wednesday – January 27 FNN News

RECOVERY trial closes recruitment to convalescent plasma treatment for patients hospitalised with COVID-19

• The RECOVERY trial was established as a randomised clinical trial to test a range of potential treatments for COVID-19.
• Since May 2020, the RECOVERY trial has included a randomised comparison of convalescent plasma vs. usual care alone.
• Convalescent plasma has been widely used as a treatment for COVID-19 but to date there has been no convincing evidence of the effect of convalescent plasma on clinical outcomes in patients admitted to hospital with COVID-19.

Source: Recovery

Sinovac: Brazil results show Chinese vaccine 50.4% effective

• A coronavirus vaccine developed by China’s Sinovac has been found to be 50.4% effective in Brazilian clinical trials, according to the latest results released by researchers.
• It shows the vaccine is significantly less effective than previous data suggested – barely over the 50% needed for regulatory approval.
• Sinovac, a Beijing-based biopharmaceutical company, is behind CoronaVac, an inactivated vaccine.
• It works by using killed viral particles to expose the body’s immune system to the virus without risking a serious disease response.

Source: BBC News

Sensitive detection of total anti-Spike antibodies and isotype switching in asymptomatic and symptomatic COVID-19 patients

• Early detection of infections is crucial to limit the spread of coronavirus 2019 disease (COVID-19).
• Here, they develop a flow cytometry-based assay to detect SARS-CoV-2 Spike protein (S protein) antibodies in COVID-19 patients.
• The assay detects specific IgM, IgA and IgG in COVID-19 patients and also the acquisition of all IgG subclasses, with IgG1 being the most dominant.

Source: ScienceDirect

Reinfection, recurrence, or delayed presentation of COVID-19? Case series and review of the literature

• Severe acute respiratory syndrome coronavirus 2 (SARS-cov-2), first described in December 2019, has now infected more than 28 million cases with almost one million deaths.
• Reinfection is not definitely established however disease recurrence is increasingly reported.
• Covid19 reinfection Recurrent COVID-19 is increasingly reported.
• However; other etiologies including superadded infection or pulmonary embolism should be ruled out, particularly if recurrence occurs less than 3 weeks.

Source: ScienceDirect

Epidemiology and pathobiology of SARS-CoV-2 (COVID-19) in comparison with SARS, MERS: An updated overview of current knowledge and future perspectives

• Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) is the causative etiology of ‘Coronavirus Disease-2019’ (COVID-19)
• This review provides an updated overview of COVID-19 (SARS-CoV-2), in comparison with the etiologies of the same group viz. SARS and MERS and also, its future perspectives for planning appropriate strategies for prevention, control and treatment modalities to avert similar catastrophe in near future.

Source: ScienceDirect

Evaluation of Aspirin Use With Cancer Incidence and Survival Among Older Adults in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial

• Many studies have evaluated the long-term benefits of aspirin use; however, the association of aspirin use with cancer incidence and survival in older individuals remains uncertain.
• This study aims to investigate the association of aspirin use with risk of developing new cancers and site-specific cancer-associated survival in bladder, breast, esophageal, gastric, pancreatic, and uterine cancers.
• In the current study, any aspirin use and aspirin use at least 3 times/week was associated with improved bladder and breast cancer survival.

Source: JAMA Network

• Download Now FNN Issue for January 2021, from this LINK.
• Read more from FADIC Blog, with many articles with evidence based articles.
• Learn More Through FADIC® – Online Programs & Mini-Courses.
• Listen Now to FADIC Podcast focusing on varieties of pharmacist perspectives in specialties.
• Read More Now about FADIC Pharmacy Events to get more Experience.

Course Copyrights:

All Courses is meant for SINGLE user use only.
If more than one person acceced this course, they will be BLOCKED Forever.

Why FADIC 2021 Clinical Research E-News ?

• It helps to keep up with the literature!
• Provide you with the Updated with the latest in your clinical practice. Wherever you are, and Whenever you need!
• Help you to share in the advance in clinical career. In addition to adding an impressive image to the pharmacists all-around!

Subscribe to FADIC 2021 Clinical Research FNN E-News, for a publication of News

Read & Download FNN Issue 8 of April 2020 FNN News